Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms, Second Primary 1Heart Failure 1Cardiotoxicity 1Breast Neoplasms 1Breast Diseases 1

Interventions

Propofol 9Sevoflurane 7Rituximab 7Magnetic Resonance Spectroscopy 6Dexamethasone 6Trastuzumab 5Specimen Handling 5Enoxaparin 5Carboplatin 5Bevacizumab 5Nivolumab 4Capecitabine 4Bupivacaine 4trametinib 3pirtobrutinib 3dabrafenib 3atezolizumab 3apixaban 3Lenalidomide 3Indocyanine Green 3Gemcitabine 3Docetaxel 3Cyclophosphamide 3zanubrutinib 2venetoclax 2trastuzumab deruxtecan 2ribociclib 2polyethylene glycol 3350 2pertuzumab 2pembrolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Recruiting × sacubitril and valsartan sodium hydrate drug combination × Clear all
NCT05465031 2025-03-14

Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)

Silesian Centre for Heart Diseases

Phase 4 Recruiting
600 enrolled
Breast

Breast Diseases, Breast Neoplasms, Heart Failure, Neoplasms, Second Primary, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡